Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 02 May 2017

Indication(s)

Treatment of osteoporosis
- in post-menopausal women
- in adult men
at increased risk of fracture, including those with a recent low-trauma hip fracture.

Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy
- in post-menopausal women
- in adult men
at increased risk of fracture.

Treatment of Paget’s disease of the bone in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Prostate Cancer

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 5 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000595
Orphan designation No
Date First Approved 15-04-2005
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Novartis Europharm Limited
Warnings

European Medicines Agency concludes class review of bisphosphonates and atypical fractures (European Medicines Agency - Press Release 15/04/2011)

Rare atypical fr